TGF-β in the central nervous system: Potential roles in ischemic injury and neurodegenerative diseases

Cytokine and Growth Factor Reviews

Volumn 8, Issue 4, 1997, Pages 267-292

  Pratt M, Bruce ^a   McPherson, John M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

AIDS dementia; Alzheimer's disease; Central nervous system; Excitotoxicity; Ischemia; Multiple sclerosis; Parkinson's disease; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ALZHEIMER DISEASE; ASTROCYTE; BRAIN ISCHEMIA; CELL PROLIFERATION; GLIA CELL; GROWTH REGULATION; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; REVIEW;

EID: 0031428894     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(97)00018-X     Document Type: Short Survey

References (253)

1. 1. Genetics Computer Group, 8 edn. Madison, Wisconsin Sequence Analysis Package, 1994.
2. 2. Wang T, Danielson P, Li B-Y, Shah P Kim S, Donahoe P. The p21RAS farnesyltransferase alpha subunit in TGF-β and activin signaling. Science 1996, 271, 1120-1122.
3. 3. Wang T, Li B-Y, Danielson P et al. The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell 1996, 86, 435-444.
4. 4. Massague J. TGFβ signaling: receptors, transducers, and MAD proteins. Cell 1996, 85, 947-950.
5. 5. Lawrence DA. Transforming growth factor-β: a general review. Eur Cytokine Netw 1996, 7, 363-374.
6. 6. Saltis J. TGF-beta: receptors and cell cycle arrest. Mol Cell Endocrinol 1996, 116, 227-232.
7. 7. Grande JP. Role of transforming growth factor-β in tissue injury and repair. Proc Soc Exp Biol Med 1997, 214, 27-40.
8. 8. Flanders K, Lüdecke G. Renzing J, Hamm C, Cissel D, Unsicker K. Effects of TFG-β's and bFGF on astroglial cell growth and gene expression in vitro. Mol Cell Neurosci 1993, 4, 406-417.
9. 9. Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MB. Transforming growth factor β isoforms in the adult rat central and peripheral nervous system. Neuroscience 1991, 44, 613-625.
10. 10. da Cunha A, Jefferson J, Jackson R, Vitkovi L. Glial cell-specific mechanisms of TGF-β1 induction by IL-1 in cerebral cortex. J Neuroimmunol 1993, 42, 71-86.
11. 11. O'Brien M, Lenke L, Lou J, Bridwell K, Joyce M. Astrocyte response and transforming growth factor-β localization in acute spinal cord injury. Spine 1994, 19, 2321-2330.
12. 12. da Cunha A, Jefferson J, Tyor W, Glass J, Jannotta F, Vitkovic L. Control of astrocytosis by interleukin-1 and transforming growth factor-β1 in human brain. Brain Res 1993, 631, 39-45.
13. 13. Knuckey NW, Finch P, Palm DE et al. Differential neuronal and astrocytic expression of transforming growth factor β isoforms in rat hippocampus following transient forebrain ischemia. Mol Brain Res 1996, 40, 1-14.
14. 14. Laping NJ, Morgan TE. Nichols NR et al. Transforming growth factor β1 induces neuronal and astrocyte genes: Tubulin alpha 1, glial fibrillary acidic protein and clusterin. Neuroscience 1994, 58, 563-572.
15. 15. Morgan TE, Laping NJ, Rozovsky I et al. Clusterin expression by astrocytes is influenced by transforming growth factor β1 and heterotypic cell interactions. J Neuroimmol 1995, 58, 101-110.
16. 16. Lindholm D, Hengerer B, Zafra F, Thoenen H. Transforming growth factor β-1 stimulates expression of nerve growth factor in the rat CNS. Neuro Report 1990, 1, 9-12.
17. 17. Constam D, Philipp J, Malipiero U, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-β1, -β2, and -β3 by glioblastoma cells, astrocytes and microglia. J Immunol 1992, 148, 1404-1410.
18. 18. da Cunha A, Vitkovic L. Transforming growth factor-beta 1 (TGF-β1) expression and regulation in rat cortical astrocytes. J Neuroimmol 1992, 36, 157-169.
19. 19. Lindholm D, Castren E, Kiefer F, Thoenen H. Transforming growth factor-β1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 1992, 117, 395-400.
20. 20. Morganti-Kossmann MC, Kossmann T, Brandes M, Mergenhagen S, Wahl S. Autocrine and paracrine regulation of astrocyte function by transforming growth factor-β. J Neuroimmol 1992, 39, 163-174.
21. 21. Pousset F. Fournier J, Legoux P, Keane P, Shire D, Soubrie P. Effect of serotonin on cytokine mRNA expression in rat hippocampal astrocytes. Mol Brain Res 1996, 38, 54-62.
22. 22. Gagelin C, Pierre M, Gavaret J-M, Toru-Delbauffe D. Rapid TGFβ1 effects on actin cytoskeleton of astrocytes: comparison with other factors and implications for cell motility. Glia 1995, 13, 283-293.
23. 23. Faber-Elman A, Solomon A, Abraham JA, Marikovsky M, Schwartz M. Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: in vitro simulation. J Clin Invest 1996, 97, 162-171.
24. 24. Toru-Delbauffe D, Baghdassarian-Chalaye D, Gavaret JM, Courtin F, Pomerance M, Pierre M. Effects of transforming growth factor β1 on astroglial cells in culture. J Neurochem 1990, 54, 1056-1061.
25. 25. Labourdette G, Thierry J. Laeng P, Perraud F, Lawrence D, Pettmann B. Transforming growth factor type β1 modulates the effects of basic fibroblast growth factor on growth and phenotypic expression of rat astroblasts in vitro. J Cell Biol 1990, 144, 473-484.
26. 26. Xiao BG, Zhang GX, Ma CG, Link H. Transforming growth factor-beta 1 (TGF-β1)-mediated inhibition of glial cell proliferation and downregulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-gamma (IFN-γ). Clin Exp Immunol 1996, 103, 475-481.
27. 27. Hunter KE, Sporn MB, Davies AM. Transforming growth factor βs inhibit mitogen-stimulated proliferation of astrocytes. Glia 1993, 7, 203-211.
28. 28. Baghdassarian D, Toru-Delbauffe D, Gavaret JM, Pierre M. Effects of transforming growth factor β1 on the extracellular matrix and cytoskeleton of cultured astrocytes. Glia 1993, 7, 193-202.
29. 29. Vergelli M, Mazzanti B, Ballerini C, Gran B, Amaducci L, Massacesi L. Transforming growth factor-β1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. J Neurosci Res 1995, 40, 127-133.
30. 30. Silberstein FC, De Simone R. Levi G, Aloisi F. Cytokine-regulated expression of platelet-derived growth factor gene and protein in cultured human astrocytes. J Neurochem 1996, 66, 1409-1417.
31. 31. Johns LD, Babcock G, Green D, Freedman M, Sriram S, Ransohoff R. Transforming growth factor-β1 differentially regulates proliferation and MHC class II antigen expression in forebrain and brainstem astrocyte primary cultures. Brain Res 1992, 585, 229-236.
32. 32. Solem M, Rawson C, Lindburg K, Barnes D. TGFβ regulates cystatin C in serum-free mouse embryo (SFME) cells. Biochem Biophys Res Comm 1990, 172, 945-951.
33. 33. Panek RB, Lee Y-J, Benveniste E. TGF-β suppression of IFN-γ induced class II MHC gene expression does not involve inhibition of phosphorylation of JAK1, JAK2 or signal transducers and activators of transcription, or modification of IFN-γ enhanced factor expression. J Immunol 1995, 154, 610-619.
34. 34. Schluesener HJ. Transforming growth factors type β1 and β2 suppress rat astrocyte autoantigen présentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-gamma and tumor necrosis factor alpha. J Neuroimmol 1990, 27, 41-47.
35. 35. Lee Y-J, Han Y, Lu H-T et al. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibition of class II transactivator messenger RNA expression. J Immunol 1997, 158, 2065-2075.
36. 36. Shrikant P, Lee SJ, Kalvakolanu I, Ransohoff R, Benveniste E. Stimulus-specific inhibition of intercellular adhesion molecule-1 gene expression by TGF-β1. J Immunol 1996, 157, 892-900.
37. 37. Shrikant P, Cluing IY, Ballestas ME. Benveniste EN. Regulation of intercellular adhesion molecule-1 gene expression by tumor necrosis factor-alpha, interleukin-1β, and interferon-γ in astrocytes. J Neuroimmunol 1994, 51, 209-220.
38. 38. Hurwitz AA, Lyman WD, Guida MP, Calderon TM, Berman JW. Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes. J Exp Med 1992, 176, 1631-1636.
39. 39. Benveniste E, Kwon J, Chung WJ, Sampson J, Pandya K, Tang LP. Differential modulation of astrocyte cytokine gene expression by TGF-β1. J Immunol 1994, 153, 5210-5221.
40. 40. Benveniste E, Tang LP, Law R. Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-β. IL-6 and IL 10. Int J Dev Neurosci 1995, 13, 341-349.
41. 41. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989, 143, 3517-3523.
42. 42. Barnum SR, Jones J. Transforming growth factor-β1 inhibits inflammatory cytokine induced C3 gene expression in astrocytes. J Immunol 1994, 152, 765-773.
43. 43. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Clin Neuroanat 1996, 10, 179-190.
44. 44. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996, 149, 21-28.
45. 45. Hooper DC, Bagasra O, Marini JC et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1997, 94, 2528-2533.
46. 46. Bukrinsky M, Nottet H, Schmidtmayerova H et al. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1(HIV-1) infected monocytes: implications for HIV-associated neurological disease. J Exp Med 1995, 181, 735-745.
47. 47. Hewett S, Corbett J, McDaniel M, Choi D. Interferon-gamma and interleukin-1β induce nitric oxide formation from primary mouse astrocytes. Neurosci Lett 1993, 164, 229-232.
48. 48. Park SK, Grzybicki D, Lin HL, Murphy S. Modulation of inducible nitric oxide synthase expression in astroglial cells. Neuropharmacology 1994, 33, 1419-1423.
49. 49. Vodovotz Y, Geiser AG, Chesler L et al. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse. J Exp Med 1996, 183, 2337-2342.
50. 50. Liu J, Zhao M-L, Brosnan C, Lee S. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1β and IL-1 receptor antagonist. J Immunol 1996, 157, 3569-3576.
51. 51. Hu S, Sheng W, Peterson P, Chao C. Differential regulation by cytokines of human astrocyte nitric oxide production. Glia 1995, 15, 491-494.
52. 52. Davies S, Beardsall K. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurons. Neurosci Lett 1992, 140, 161-164.
53. 53. Shigeno T, Mima T, Takakura K et al. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J Neurosci 1991, 11, 2914-2919.
54. 54. Yamamoto S, Yoshimine T, Fujita T et al. Protective effect of NGF atelocollagen mini-pellet on the hippocampal delayed neuronal death in gerbils. Neurosci Lett 1992, 141, 161-165.
55. 55. Buchan A, Williams L, Bruederlin B. Nerve growth factor: pretreatment ameliorates ischemic hippocampal neuronal injury. Stroke 1992, 21, 177.
56. 56. Hahn M, Lorez H, Fischer G. The immortalized astroglial cell line RC7 is a new model system for the study of nerve growth factor regulation: stimulation by interleukin-1β and transforming growth factor-β1 is additive and affected differently by dibutyryl cyclic AMP. Glia 1994, 10, 286-295.
57. 57. Zafra F, Lindholm D, Castren E, Hartikka J, Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J Neurosci 1992, 12, 4793-4799.
58. 58. Chao C, Hu S, Tsang M, Weatherbee J, Molitor T. Effects of transforming growth factor-β on murine astrocyte glutamine synthetase activity. J Clin Invest 1992, 90, 1786-1793.
59. 59. Hurwitz A, Lyman W, Berman J. Tumor necrosis factor alpha and transforming growth factor β upregulate astrocyte expression of monocyte chemoattractant protein-1. J Neuroimmunol 1995, 57, 193-198.
60. 60. Yao J, Harvath L, Gilbert DL, Colton CA. Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 1990, 27, 36-42.
61. 61. Hu S, Sheng W. Peterson P, Chao C. Cytokine modulation of murine microglial cell superoxide production. Glia 1995, 13, 45-50.
62. 62. Batuman O, Ferrero A, Cupp C, Jimenez S, Khalili K. Differential regulation of transforming growth factor β1 gene expression by glucocorticoids in human T and glial cells. J Immunol 1995, 155, 4397-405.
63. 63. Chao C, Hu S, Sheng W, Tsang M, Peterson P. Tumor necrosis factor-alpha mediates the release of bioactive transforming growth factor β in murine microglial cell cultures. Clin Immunol Immunopathol 1995, 77, 358-365.
64. 64. Chao CC, Hu S, Sheng WS, Peterson P. Tumor necrosis factor-alpha production by human fetal microglial cells: regulation by other cytokines. Dev Neurosci 1995, 17, 97-105.
65. 65. Suzumura A, Sawada M, Yamamoto H, Marunouchi T. Transforming growth factor-β suppresses activation and proliferation of microglia in vitro. J Immunol 1993, 151, 2150-2158.
66. 66. Chao C, Hu S, Peterson P. Modulation of human microglial cell superoxide production by cytokines. J Leuk Biol 1995, 58, 65-70.
67. 67. Lodge P, Sriram S. Regulation of microglial activation by TGF-β, IL-10 and CSF-1. J Leuk Biol 1996, 60, 502-508.
68. 68. Panek R B, Benveniste EN. Class II MHC gene expression in microglia. J Immunol 1995, 154, 2846-2854.
69. 69. Gehrmann J, Banati RB, Wiessner C, Hossmann KA, Kreutzberg GW. Reactive microglia in cerebral ischaemia: an early mediator of tissue damage. Neuropathol Appl Neurobiol 1995, 21, 277-289.
70. 70. Chao C, Hu S, Peterson P, Glia: the not so innocent bystanders. J Neurovirol 1996, 2, 234-239.
71. 71. McKinnon RD, Piras G, Ida JA Jr, Dubois Dalcq M. A role for TGF-β in oligodendrocyte differentiation. J Cell Biol 1993, 121, 1397-1407.
72. 72. Zola-Morgan S, Squire L, Amaral D. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986, 6, 2950-2967.
73. 73. Zola-Morgan S, Squire L, Rempel N, Clower R, Amaral D. Enduring memory impairment in monkeys after ischemic damage to the hippocampus. J Neurosci 1992, 12, 2582-2596.
74. 74. Ohno M, Watanabe S. Concurrent blockade of hippocampal metabotropic glutamate and N-methyl-D-aspartale receptors disrupts working memory in the rat. Neuroscience 1996, 70, 303-311.
75. 75. Ueki A, Miwa C, Oohara K, Miyoshi K. Histological evidence for cholinergic alteration in the hippocampus following entorhinal cortex lesion. J Neurol Sci 1996, 142, 7-11.
76. 76. Rami A, Krieglstein J. Brain damage caused by ischemia: pathophysiological and pharmacological aspects. Dementia 1993, 4, 21-31.
77. 77. Wilcox J, Derynck R, Localization of cells synthesizing transforming growth factor-alpha mRNA in the mouse brain. J Neurosci 1988, 8, 1901-1904.
78. 78. Heine U, Munoz EF, Flanders KC et al. Role of transforming growth factor-β in the development of the mouse embryo. J Cell Biol 1987, 105, 2861-2876.
79. 79. Klempt ND, Sirimanne E, Gunn AJ et al. Hypoxia-ischemia induces transforming growth factor β1 mRNA in the infant rat brain. Mol Brain Res 1992, 13, 93-101.
80. 80. Wang X, Yue T-L, White R, Barone F, Geuerstein G. Transforming growth factor-β1 exhibits delayed gene expression following focal cerebral ischemia. Brain Res Bull 1995, 36, 607-609.
81. 81. Wießner C, Gehrmann J, Lindholm D, Topper R, Kreutzberg GW, Hossmann KA. Expression of transforming growth factor-β1 and interleukin-β1 mRNA in rat brain following transient forebrain ischemia. Acta Neuropathol 1993, 86, 439-446.
82. 82. Lehrmann E, Kiefer R, Finsen B, Diemer NH, Zimmer J, Hartung H-P. Cytokines in cerebral ischemia: expression of transforming growth factor beta-1 (TGF-β1) mRNA in the postichemic adult rat hippocampus. Exp Neurol 1995, 131, 114-123.
83. 83. Krupinski J, Kumar P, Kumar S, Path F, Kaluza J. Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke 1996, 27, 852-857.
84. 84. Gross C, Bednar M, Howard D, Sporn M. Transforming growth factor-β1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993, 24, 558-562.
85. 85. Gross C, Howard D, Dooley R, Raymond S, Fuller S, Bednar M. TGFβ1 post-treatment in a rabbit model of cerebral ischaemia. Neurol Res 1994, 16, 465-470.
86. 86. Prehn J, Backhauß C, Krieglstein J. Transforming growth factor-β1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Melab 1993, 13, 521-525.
87. 87. Henrich-Noack P, Prehn JHM, Krieglstein J. Neuroprotective effects of TGF-β1. J Neural Transm 1994, 43, 33-45.
88. 88. Henrich-Noack P, Prehn JHM, Krieglstein J. TGF-β1 protects hippocampal neurons against degeneration caused by transient global ischemia. Stroke 1996, 27, 1609-1615.
89. 89. Henrich-Noack P, Krieglstein J, Prehn JHM. TGFβ1 protects hippocampal neurons from ischemic injury: evaluation of potential neuroprotective mechanisms. J Cereb Blood Flow Metab 1995, 15, S403.
90. 90. McNeill H, Williams C, Guan J et al. Neuronal rescue with transforming growth factor β1 after hypoxic-ischaemic brain injury. Neuroreport 1994, 5, 901-904.
91. 91. Williams C, Guan J, Miller O et al. The role of the growth factors IGF-1 and TGFβ1 after hypoxic-ischemic brain injury. Ann NY Acad Sci 1995, 765, 306-307.
92. 92. Lefer A, Tsao P, Aoki N, Palladino M. Mediation of cardioprotection by transforming growth factor-β. Science 1990, 249, 61-64.
93. 93. Roberts A, Sporn M, Lefer A. Cardioprotective actions of transforming growth factor-β. Trends Cardiovasc Med 1993, 3, 77-81.
94. 94. Thomas GR, Thibodaux H. Transforming growth factor-β1 inhibits postischemic increases in splanchnic vascular resistance. Biotechnol Therap 1992, 3, 91-100.
95. 95. Karasawa A, Guo J-P, Ma X-L, Lefer A. Beneficial effects of transforming growth factor-β and tissue plasminogen activator in splanchnic artery occlusion and reperfusion in cats. J Cardiovasc Pharmacol 1991, 18, 95-105.
96. 96. Lefer AM, Ma X-L, Weyrich AS, Scalia R. Mechanism of the Cardioprotective effect of transforming growth factor β1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 1993, 90, 1018-1022.
97. 97. Riedel G, Reymann KG. Metabotropic glutamate receptors in hippocampal long-term potentiation and learning and memory. Acta Physiol Scand 1996, 157, 1-19.
98. 98. Miller S, Kesslak JP, Romano C, Cotman C. Roles of metabotropic glutamate receptors in brain plasticity and pathology. Ann NY Acad Sci 1995, 757, 460-474.
99. 99. Kaczmarek L, Kossut M, Skangiel-Kramska J. Glutamate receptors in cortical plasticity: molecular and cellular biology. Physiol Rev 1997, 77, 217-255.
100. 100. Hollmann M, Heinemann S. Cloned glutamate receptors. Ann Rev Neurosci 1994, 17, 31-108.
101. 2+: their relationship to apoptosis and oncogenesis. FEBS Lett 1993, 325, 104-107.
102. 102. White RJ, Reynolds I. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitoloxin exposure. J Neurosci 1996, 16, 5688-5697.
103. 2+ influx underlies potent induction of injury. J Neurosci 1996, 16, 5457-5465.
104. 104. Budd S, Nicholls D. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996, 67, 2282-2291.
105. 2+ entry. NeuroReport 1995, 6, 1089-1092.
106. 2+ loads by mitochondria in cultured rat hippocampal neurons. J Neurophysiol 1996, 76, 1611-1621.
107. 2+ dependent. Neurosci Lett 1994, 167, 93-96.
108. 2+ dependent collapse of mitochondrial membrane potential and ultrastructural alterations of mitochondria. FEBS Lett 1996, 392, 143-147.
109. 109. Prehn JHM, Miller R. Opposite effects of TGF-Jβ1 on rapidly and slowly triggered excitotoxic injury. Neurol Res 1996, 35, 249-256.
110. 110. Choi D. Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res 1994, 100, 47-51.
111. 111. Ankarcrona M, Dypbukt J, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton S. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995, 15, 961-973.
112. 112. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P. Lipton S. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci 1995, 92, 7162-7166.
113. 113. Kaku D, Giffard R, Choi D. Neuroprotective effects of glutamate antagonists and extracellular acidity. Science 1993, 260, 1516-1518.
114. 114. Dingledine, R, Excitatory amino acid transmitters In Basic Neurochemistry: Molecular, Cellular And Medical Aspects, 5th edn, ed G Siegel New York, Raven Press, 1994, pp 368-384.
115. 115. Williams K, Romano C, Dichter M, Molinoff P. Modulation of the NMDA receptor by polyamines. Life Sci 1991, 48, 469-498.
116. 116. Prehn J, Peruche B, Unsicker K. Krieglstein J. Isoform-specific effects of transforming growth factors-β on degeneration of primary neuronal cultures induced by cytotoxic hypoxia or glutamate. J Neurochem 1993, 60, 165-1672.
117. 117. Prehn J, Bindokas V, Marcuccilli C, Krajewksi S, Reed J, Miller R. Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type β confers wide ranging protection on rat hippocampal neurons. Proc Natl Acad Sci 1994, 91, 12599-12603.
118. 118. Prehn JHM. Marked diversity in the action of growth factors on N-methyl-D-aspartate-induced neuronal degeneration. Eur J Pharmacol 1996, 306, 81-88.
119. 119. Tomoda T, Shirasawa T, Yahagi Y-I et al. Transforming growth factor β is a survival factor for neonate cortical neurons: coincident expression of type I receptors in developing cerebral cortices. Dev Biol 1996, 179, 79-90.
120. 120. Murphy AN, Bredesen D, Cortopassi G, Wang E, Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 1996, 93, 9892-9898.
121. 2+. Oncogens 1996, 12, 2259-2266.
122. 122. Myers KM, Fiskum G, Lin Y, Simmens S, Bredesen D, Murphy A. Bcl-2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial injury, and loss of viability. J Neurochem 1995, 65, 2432-2440.
123. 123. Lawrence M, Ho DY, Sun GH, Steinberg G, Sapolsky R. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J Neurosci 1996, 16, 486-496.
124. 124. Takenaka I, High tower L. Transforming growth factor-β1 rapidly induces Hsp70 and Hsp90 molecular chaperones in cultured chicken embryo cells. J Cell Physiol 1992, 152, 568-577.
125. 125. Takenaka I, Hightower L. Regulation of chicken Hsp70 and Hsp90 family gene expression by transforming growth factor β1. J Cell Physiol 1993, 155, 54-62.
126. 126. Dawson V, Dawson T, London E, Bredt D, Snyder S. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991, 88, 6368-6371.
127. 127. Lefebvre PP, Staecker H, Weber T, Van de Water TR, Register B, Moonen G. TGFβ1 modulates bFGF receptor message expression in cultured adult auditory neurons. NeuroReport 1991, 2, 305-308.
128. 128. Grothe C, Wewetzer K. Fibroblast growth factor and its implications for developing and regenerating neurons. Acta Orthop Scand 1996, 40, 403-410.
129. 129. Kane CJM, Brown GJ, Phelan KD. Transforming growth factor-β3 increases NMDA receptor-mediated excitotoxicity in rat cerebral cortical neurons independently of glia. Neurosci Lett 1996, 204, 93-96.
130. 130. Prehn JHM, Krieglstein J. Opposing effects of transforming growth factor-β1 on glutamate neurotoxicity. Neuroscience 1994, 60, 7-10.
131. 131. Koh J-Y, Gwang B, Lobner D, Choi D. Potentiated necrosis of cultured cortical neurons by neurotrophins. Science 1995, 268, 573-575.
132. 132. Cannella B, Raine C. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995, 37, 424-435.
133. 133. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993, 5, 583-588.
134. 134. Peress N, Perillo E, Seidman R. Glial transforming growth factor (TGF)-β isotypes in multiple sclerosis: differential glial expression of TGF-β1, 2, and 3 isotypes in multiple sclerosis. J Neuroimmunol 1996, 71, 115-123.
135. 135. Link, J. Interferon-γ, interleukin-4 and transforming growth factor-β mRNA expression in multiple sclerosis and myasthenia gravis Acta Neurol Scand. 1994, Supplement 158, 5-58.
136. 136. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl Å, Link H. Increased transforming growth factor-β, interleukin-4 and interferon-gamma in multiple sclerosis. Ann Neurol 1994, 36, 379-386.
137. 137. Rieckmann P, Albrecht M, Kitze B et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994, 44, 1523-1526.
138. 138. Beck J, Rondot P, Jullien P, Wietzerbin J, Lawrence DA. TGF-β-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 1991, 84, 452-455.
139. 139. Mokhtarian F, Shi Y, Shirazian D, Morgante L, Miller A, Grob D. Defective production of anti-inflammatory cytokine. TGF-β by T cell lines of patients with active multiple sclerosis. J Immunol 1994, 152, 6003-6010.
140. 140. Correale J, Gilmore W. McMillan M et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995, 154, 2959-2968.
141. 141. Link J, He B, Vaidrius N, Palasik W, Fredrikson S, Soderstrom M. Transforming growth factor-β suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmol 1995, 58, 21-35.
142. 142. Link J, Soderstrom M, Kostulas V et al. Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-gamma, interleukin-4 and transforming growth factor-β. J Neuroimmol 1994, 49, 9-18.
143. 143. Link J, Fredrikson S, Soderstrom M et al. Organ-specific autoantigens induce transforming growth factor-β mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann Neurol 1994, 35, 197-203.
144. 144. Santambrogio L, Hochwald G, Saxena B et al. Studies on the mechanisms by which transforming growth factor-β (TGF-β) protects against allergic encephalomyelitis. J Immunol 1993, 151, 1116-1127.
145. 145. Issazadeh S, Mustafa M, Ljungdahl Å et al. Interferon gamma, interleukin 4 and transforming growth factor β in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995, 40, 579-590.
146. 146. Johns L, Flanders K, Ranges G, Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J Immunol 1991, 147, 1792-1796.
147. 147. Racke MK, Cannella B, Albert P, Sporn M, Raine CS, McFarlin DE. Evidence of endogenous regulatory function of transforming growth factor-β1 in experimental allergic encephalomyelitss. Int Immunol 1992, 4, 615-620.
148. 148. Issazadeh S, Lorentzen J, Mustafa M. Hojeberg B, Mussener Å, Olsson T. Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-β. J Neuroimmol 1996, 69, 103-115.
149. 149. Tanuma N, Kojima T, Shin T et al. Competitive PCR quantification of pro-and anti-inflammatory cytokine mRNA in the central nervous system during autoimmune encephalomyelitis. J Neuroimmol 1997, 73, 197-206.
150. 150. Santambrogio L, Hochwald GM, Leu CH, Thorbeck GJ. Antagonistic effects of endogenous and exogenous TGF-β and TNF on auto-immune diseases in mice. Immunopharmacol Imunotoxicol 1993, 15, 461-478.
151. 151. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991, 88, 2918-2921.
152. 152. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J Immunol 1991, 146, 3012-3017.
153. 153. Stevens D, Gould K, Swanborg R. Transforming growth factor-β1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J Neuroimmunol 1994, 51, 77-83.
154. 154. Racke MK, Sriram S, Carlino J, Cannella B, Raine CS, McFarlin DE. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor β2. J Immunol 1993, 46, 175-184.
155. 155. Santambrogio L, Crisi GM, Leu J, Hochwald GM, Ryan T, Thorbecke GJ. Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis. J Neuroimmunol 1995, 58, 211-222.
156. 156. Johns L, Sriram S. Experimental allergic encephalomyelitis: neutralizing antibody to TGFβ1 enhances the clinical severity of the disease. J Neuroimmunol 1993, 47, 1-7.
157. 157. Weiner H. Oral tolerance for the treatment of autoimmune diseases. Anna Rev Med 1997, 48, 341-351.
158. 158. Inobe J, Chen Y, Weiner HL. In vivo administration of IL-4 induces TGF-β producing T cells and protects animals from experimental autoimmune encephalomyelitis. Ninth International Congress of Immunology, 1995.
159. 159. Harbige LS, Layward L, Amor S, Morris MM, Dumonde DC. The protective effect of linoleic acid and gamma-linoleic acid-rich lipid in EAE is associated with TGF-β1 production. Ninth International Congress of Immunology, 1995.
160. 160. Mustafa M, Vingsbo C, Olsson T, Ljungdahl Å, Hojeberg B, Holmdahl R. The major histocompatibility complex influences myelin basic protein 63-88 induced T cell cytokine profile and experimental autoimmune encephalomyelitis. Eur J Immunol 1993, 23, 3089-3095.
161. 161. Mustafa M, Vingsbo C, Olsson T, Issazadeh S, Ljungdahl Å, Holmdahl R. Protective influences on experimental autoimmune encephalomyelitis by MHC Class I and Class II alleles. J Immunol 1994, 153, 3337-3344.
162. 162. Mokhtarian F, Shi Y, Zhu P-F, Grob D. Immune responses, and autoimmune outcome, during virus infection of the central nervous system. Cell Immunol 1994, 157, 195-210.
163. 163. Maller A, Lider O, Roberts A, Sporn M, Weiner H. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in viro immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992, 89, 421-425.
164. 164. Miller A, Al-Sabbagh A, Santos L, Das MP, Weiner H. Epitopes of myelin basic protein that trigger TGF-β release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J Immunol 1993, 151, 7307-7315.
165. 165. Chen Y, Inobe J, Weiner HL. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J Immunol 1995, 155, 910-916.
166. 166. Santos L, Al-Sabbagh A, Londono A, Weiner H. Oral tolerance to myelin basic protein induces regulatory TGF-β secreting T cells in Peyer's patches of SJL mice. Cell Immunol 1994, 157, 439-447.
167. 167. Fukaura H, Kent S, Pietrusewicz M, Khoury S, Weiner H, Hafler D. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1 secreting Th3 T cells by oral administration of myelin in multiple sclerosis. J Clin Invest 1996, 98, 70-77.
168. 168. Khoury S, Hancock W, Weiner H. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992, 176, 1355-1364.
169. 169. Gamble J, Vadas M. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-β. Science 1988, 242, 97-99.
170. 170. Gamble J, Vadas M. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β1. J Immunol 1991, 146, 1149-1154.
171. 171. McCarron RM, Wang L, Racke MK, McFarlin DE, Spatz M. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascuiar endothelial cells. J Neuroimmol 1993, 43, 23-30.
172. 172. Fabry Z, Topham D, Fee D et al. TGF-β2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J Immunol 1995, 155, 325-332.
173. 173. Savage CO, Brooks CJ, Adu D, Richards G, Howie AJ. Cell adhesion molecule expression within human glomerular and kidney organ culture. J Pathol 1997, 181, 111-115.
174. 174. Fabry Z, Waldschmidt MM, Hendrickson D et al. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55. J Neuroimmol 1992, 36, 1-11.
175. 175. Swerlick RA, Garcia-Gonzalez E, Kubota Y, Xu YL, Lawley TJ. Studies of the modulation of MHC antigen and cell adhesion molecule expression on human dermal microvascular endothelial cells. J Invest Dermatol 1991, 97, 190-196.
176. 176. Ransohoff R, Estes M. Astrocyte expression of major histocompatibility complex gene products in multiple sclerosis brain tissue obtained by stereotactic biopsy. Arch Neurol 1991, 48, 1244-1246.
177. 177. Ransohoff R, Devajyothi C, Estes M et al. Interferon-β specifically inhibits interferon gamma induced class II major histocompatibitity complex gene transcription in a human astrocytoma cell line. J Neuroimmol 1991, 33, 103-112.
178. 178. Kreutzberg GW. Microglia, the first line of defense in brain pathologies. Arzneimittelforschung 1995. 45, 357-360.
179. 179. Devajyothi C, Kalvakolanu I, Babcock G, Vasavada H, Howe P, Ransohoff R. Inhibition of interferon-γ-induced major histocompatiblity complex class II gene transcription by interferon-β and type β1 transforming growth factor in human astrocytoma cells. J Biol Chem 1993, 268, 18794-18800.
180. 180. Merrill J, Ignarro L, Sherman M, Melinek J, Lane T. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993, 151, 2132-2141.
181. 181. Zielasek J, Jung S, Gold R, Liew FY, Toyka KV, Hartung HP. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995, 58, 81-88.
182. 182. Brosnan C, Battistini L, Raine C, Dickson D, Casadevall A, Lee S. Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 1994, 16, 152-161.
183. 183. Forstermann U, Closs E, Pollock J et al. Nitric oxide synthase isozymes. Hypertension 1994, 23, 1121-1131.
184. 184. Shindo T, Ikeda U, Ohkawa F et al. Nitric oxide synthesis in rat cardiac myocytes and fibroblasts. Life Sci 1994, 55, 1101-1108.
185. 185. Perrella M, Yoshizumi M, Fen Z et al. Transforming growth factor-β1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1β in rat smooth muscle cells. J Biol Chem 1994, 269, 14595-14600.
186. 186. Chesrown S, Monnier J, Visner G, Nick H. Regulation of inducible nitric oxide synthase mRNA levels by LPS, INF-γ, TGF-β, and IL-10 in murine macrophage cell lines and rat peritoneal macrophages. Biochem Biophys Res Comm 1994, 200, 126-134.
187. 187. Gilbert RS, Herschman H. Transforming growth factor β differentially modulates the inducible nitric oxide synthase gene in distinct cell types. Biochem Biophys Res Comm 1993, 195, 380-384.
188. 188. Jun CD, Choi BM, Kim SU, Lee SY, Kim HM, Chung HT. Down-regulation of transforming growth factor-β gene expression by antisense oligodeoxynucleotides increases recombinant interferon-γ induced nitric oxide synthesis in murine peritoneal macrophages. Immunology 1995, 85, 114-119.
189. 189. Merrill J, Zimmerman R. Natural and induced cytotoxicity of oligodendrocytes by microglia is inhibitable by TGFβ. Glia 1991, 4, 327-331.
190. 190. Koprowski H, Zheng YM, Heber-Katz E et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA 1993, 90, 3024-3027.
191. 191. Lin RF, Lin T-S, Tilton RG, Cross AH. Nitric oxide localised to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study. J Exp Med 1993, 178, 643-648.
192. 192. Van Dam A-M, Bauer J, Man-A-Hing WKH, Marquette C, Tilders FJH, Berkenbosch F. Appearance of inducible nitric oxide synthase in the rat central nervous system after rabies virus infection and during experimental allergic encephalomyelitis but not after peripheral administration of endotoxin. J Neurosci Res 1995, 40, 251-260.
193. 193. Reiling N, Ulmer AJ, Duchrow M, Ernst M, Flad H-D, Hauschildt S. Nitric oxide synthase: mRNA expression of different isoforms in human monocytes/macrophages. Eur J Immunol 1994, 24, 1941-1944.
194. 194. Tracey RW, Chun X, Klinghofer V et al. Immunochemical detection of inducible NO synthase in human lung. Am J Physiol 1994, 266, L722-L727.
195. 195. Denis M. Human monocytes/macrophages: NO or no NO?. J Leuk Biol 1994, 123, 129-140.
196. 196. Bo L, Dawson T, Wesselingh S et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994, 36, 778-786.
197. 197. Edwards R. Pathogenesis of Parkinson's disease. Clin Neurosci 1993, 1, 36-44.
198. 198. Chalazonitis A, Kalberg J, Twardzik D, Morrison R, Kessler J. Transforming growth factor β has neurotrophic actions on sensory neurons in vitro and is synergistic with nerve growth factor. Dev Biol 1992, 152, 121-132.
199. 199. Martinou J-C, Le Van Thai A, Valette A, Weber M. Transforming growth factor β1 is a potent survival factor for rat embryo motoneurons in culture. Dev Brain Res 1990, 52, 175-181.
200. 200. Gouin A, Bloch-Gallego E, Tanaka H, Rosenthal A, Henderson CE. Transforming growth faclor-β3, glial cell line-derived neurotrophic factor, and fibroblast growth factor-2, act in different manners to promote motoneuron survival in vitro. J Neurosci Res 1996, 43, 454-464.
201. 201. Ishihara A, Saito H, Abe K. Transforming growth factor-β1 and β2 promote neurite sprouting and elongation of cultured rat hippocampal neurons. Brain Res 1994, 639, 21-25.
202. 202. Krieglstein K, Unsicker K. Transforming growth factor β1 promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity. Neuroscience 1994, 63, 1189-1196.
203. 203. Krieglstein K, Suter-Crazzolara C, Fischer W, Unsicker K. TGF-β superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J 1995, 14, 736-742.
204. 204. Krieglstein K, Maysinger D, Unsicker K. The survival response of mesencephalic dopaminergic neurons to the neurotrophins BDNF and NT-4 requires priming with serum: comparison with members of the TGF-β superfamily and characterization of the serum-free culture system. J Neural Transm 1996, 47, 247-258.
205. 205. Unsicker K, Suter-Crazzalora C, Krieglstein K. Growth factor function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF-β CIBA Found Symp, 1996, 196, 70-80; discussion 80-84.
206. 206. Poulsen KT, Armanini MP, Klein RD, Hynes MA, Phillips HS, Rosenthal A. TGFβ2 and TGFβ3 are potent survival factors for midbrain dopaminergic neurons. Neuron 1994, 13, 1245-1252.
207. 207. Sauer H, Rosenblad C, Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 1995, 92, 8935-8939.
208. 208. Mogi M, Harada M, Kondo T, Narabayashi H, Riedcrer P, Nagatsu T. Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 1995, 193, 129-132.
209. 209. Vawter M, Dillon-Carter O, Tourtellotte WW, Carvey P, Freed W. TGFβ1 and TGFβ2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol 1996, 142, 313-322.
210. 210. McKhann G, Drachman D, Folstein M, Katzman R, Price D. Clinical diagnosis of Alzheimer's disease. Neurology 1984, 34, 939-944.
211. 211. Selkoe DJ. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994, 10, 373-403.
212. 212. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994, 17, 489-517.
213. 213. Frautschy SA, Baird A, Cole GM. Effects of injected Alzheimer β-amyloid cores in rat brain. Proc Natl Acad Sci USA 1991, 88, 8362-8366.
214. 214. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990, 250, 279-282.
215. 215. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995, 9, 21-30.
216. 216. Bodmer S, Podlisny M, Selkow D, Heid I, Fontana A. Transforming growth factor-β bound to soluble derivatives of the β amyloid precursor protein of Alzheimer's disease. Biochem Biophys Res Comm 1990, 171, 890-897.
217. 217. van der Wal EA, Gomez-Pinilla F, Cotman CW. Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. NeuroReport 1993, 4, 69-72.
218. 218. Peress N, Perillo E. Differential expression of TGF-β1, 2, and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 1995, 54, 802-811.
219. 219. Frautschy SA, Yang F, Calderon L, Cole GM. Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol Aging 1996, 17, 311-321.
220. 220. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-β in Alzheimer's disease. Neurology 1995, 45, 1561-1569.
221. 221. Chao C, Ala T, Hu S et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1994, 1, 433-436.
222. 222. Chao C, Hu S, Frey W, Ala T, Tourtellotte W, Peterson P. Transforming growth factor β in Alzheimer's disease. Clin Diagn Lab Immunol 1994, 1, 109-110.
223. 223. Gray C, Patel A. Regulation of β-amyloid precursor protein isoform mRNAs by transforming growth factor-β1 and interleukin-1β astrocytcs. Mol Brain Res 1993, 19, 251-256.
224. 224. Monning U, Sandbrink R, Banati R, Masters C, Beyreuther K. Transforming growth factor β mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Lett 1994, 342, 267-272.
225. 225. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I. Rydel R. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurol Sci 1992, 12, 376-389.
226. 226. Wolozin B, Hirashima N, Luo Y et al. Transforming growth factor β induces Aβ responsive calcium fluxes in neurons. NeuroReport 1995, 6, 1429-1433.
227. 227. Choi-Miura N-h, Oda T. Relationship between multifunctional protein "clusterin" and Alzheimer disease. Neurobiol Aging 1996, 17, 717-722.
228. 228. Boggs LN, Fuson KS, Baez M et al. Clusterin (Apo J) protects against in vitro amyloid-β (1-40) neurotoxicity. J Neurochem 1996, 67, 1324-1327.
229. 229. Oda T, Wals P, Osterburg HH et al. Clusterin (apo J) alters the aggregation of amyloid β-peptide (Aβ 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 1995. 136, 22-31.
230. 230. Chao C, Hu S, Kravitz F, Tsang M, Anderson WR, Peterson P. Transforming growth factor β protects human neurons against β-amyloid-induced injury. Mol Chem Neuropathol 1994, 23, 159-178.
231. 231. Prehn J, Bindokas V, Jordan J et al. Protective effect of transforming growth factor-β1 on β-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol 1996, 49, 319-328.
232. 232. Ren RF, Flanders KC. Transforming growth factors-β protect primary rat hippocampal neuronal cultures from degeneration induced by β-amyloid peptide. Brain Res 1996, 732, 16-24.
233. 233. Goodman Y, Rydel RE, Culwell AR, Mattson MP. Secreted forms of βAPP protect hippocampal neurons against Aβ toxicity and oxidative injury. Soc Neurosci Abs 1993, 19, 1251.
234. 234. Kekow J, Wachsman W, McCutchan JA, Cronin M, Carson D, Lotz M. Transforming growth factor β and non-cytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 1990, 87, 8321-8325.
235. 235. Wahl SM, Allen JB, McCartney-Francis N et al. Macrophage-and astrocyte-derived transforming growth factor β as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 1991, 173, 981-989.
236. 236. Kekow J, Wachsman W, McCutchan JA et al. Transforming growth factor-β and suppression of humoral immune responses in HIV infection. J Clin Invest 1991, 87, 1010-1016.
237. 237. Johnson MD, Gold LI. Distribution of transforming growth factor-β isoforms in human immunodeficiency virus-1 encephalitis. Hum Pathol 1996, 27, 643-649.
238. 238. da Cunha A, Jackson R, Vitkovic L. HIV-1 non-specifically stimulates production of transforming growth factor-β1 transfer in primary astrocytes. J Neuroimmunol 1995, 60, 125-133.
239. 239. Zauli G, Davis B, Re MC, Visani G, Furlini G, La Placa M. Tat protein stimulates production of transforming growth factor-β1 by marrow macrophages: a potential mechanism for human immunodeficiency virus-1 induced hematopoietic suppression. Blood 1992, 80, 3036-3043.
240. 240. Cupp C, Taylor JP, Khalili K, Amini S. Evidence for stimulation of the transforming growth factor β1 promoter by HIV-1 Tat in cells derived from CNS. Oncogene 1993, 8, 2231-2236.
241. 241. Rasty S, Thatikunta P, Gordon J, Khalili K, Amini S, Glorioso J. Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor β1 gene expression. Proc Natl Acad Sci USA 1996, 93, 6073-6078.
242. 242. Lazdins JK, Klimkait T, Alteri E et al. TGF-β: up-regulator of HIV replication in macrophages. Ren Virol 1991, 142, 239-242.
243. 243. Lazdins JK, Klimkait T, Woods-Cook K et al. In vitro effect of transforming growth factor-β on progression on HIV-1 infection in primary mononuclear phagocytes. J Immunol 1991, 147, 1201-1207.
244. 244. Poli G, Kinter A, Justement J, Bressler P, Kehrl J, Fauci A. Transforming growth factor-β suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med 1991, 173, 589-597.
245. 245. Price R. Understanding the AIDS dementia complex (ADC) In HIV, AIDS and the Brain, ed RW Price and SW Perry, Raven Press, New York, 1994, pp 1-45.
246. 246. Masliah E. In vivo modeling of HIV-1 mediated neurodegeneration. Am J Pathol 1996, 149, 745-750.
247. 247. Benveniste E. Cytokine circuits in brain. Implications for AIDS dementia complex. Res Publ Assoc Nerv Ment Dis 1994, 72, 71-88.
248. 248. Yoshioka M, Bradley W, Shapshak P et al. Role of immune activation and cytokine expression in HIV-1 associated neurologic diseases. Adv Neuroimmunol 1995, 5, 335-358.
249. 249. Merrill, J and Maza-Martinez, O. Cytokines in AIDS-associated nervous and immune system dysfunction In Neurobiology of Cytokines, ed EB DeSouza Academic Press, San Diego, CA, 1993, pp 243-266 (Methods in Neurosciences; vol 17).
250. 249. Merrill, J and Maza-Martinez, O. Cytokines in AIDS-associated nervous and immune system dysfunction In Neurobiology of Cytokines, ed EB DeSouza Academic Press, San Diego, CA, 1993, pp 243-266 (Methods in Neurosciences; vol 17).
251. 250. Wahl SM, Hunt DA, Wakefield LM et al. Transforming growth factor β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987, 84, 5788-5792.
252. 251. Wyss-Coray T, Feng L, Masliah E et al. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am J Pathol 1995, 147, 53-67.
253. 252. Meucci O, Miller R. gp120-Induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-β1. J Neurosci 1996, 16, 4080-4088.